

ELITE PHARMACEUTICALS INC /DE/  
Form NT 10-Q  
August 17, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

Commission File Number: 001-15697

(Check One):  Form 10-K  Form 20-F  Form 11-K  Form 10-Q  Form N-SAR  Form N-CSR

For Period Ended: **June 30, 2009**

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: \_\_\_\_\_

Read attached instruction sheet before preparing form. Please print or type.  
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

---

**PART I -- REGISTRANT INFORMATION**

**ELITE PHARMACEUTICALS, INC.**

-----  
Full name of registrant:

-----  
Former name if applicable:

**165 Ludlow Avenue**

-----  
Address of principal executive office (Street and number):

**Northvale, New Jersey 07647**

-----  
City, state and zip code

---

**PART II -- RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- [ X ] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached

**PART III -- NARRATIVE**

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The Company has experienced a delay in completing and/or obtaining the information necessary in order to prepare its Form 10-Q Quarterly Report for the period ended June 30, 2009 (the [ ]Quarterly Report[ ]). The Company expects to file its Quarterly Report within the allotted relief period.

**PART IV -- OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

|                                |                               |                                         |
|--------------------------------|-------------------------------|-----------------------------------------|
| Carter Ward<br>-----<br>(Name) | (201)<br>-----<br>(Area Code) | 750-2646<br>-----<br>(Telephone Number) |
|--------------------------------|-------------------------------|-----------------------------------------|

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). [X] Yes [ ] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [ X ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**ELITE PHARMACEUTICALS, INC.**

-----  
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 17, 2009

/s/ Carter Ward  
Carter Ward  
Chief Financial Officer